An Open-Label, Randomized, Double-Arm Clinical Trial to Compare the Effectiveness and Safety of Super Bioavailable Itraconazole Capsules and Itraconazole Capsules in the Management of Dermatophytosis in India

Purpose A new oral formulation of itraconazole, called super bioavailable itraconazole (SBITZ), has been launched in India, exhibiting greater bioavailability than conventional itraconazole (CITZ). No clinical studies on its effectiveness and safety in dermatophytosis in comparison with CITZ have been conducted in India. Hence, the aim of this clinical study was to compare the effectiveness and safety of SBITZ capsules and CITZ capsules in dermatophytosis. Patients and Methods This was an open-label, randomized, double-arm clinical study in which 70 patients (≥18 years of age) of either gender and diagnosed with tinea cruris, tinea corporis, and/or tinea faciei were included. The study was divided into two parts, the first part comprising a treatment period of 4 weeks and the second part an observation period for recurrence, comprised of another 4 weeks, thus making an entire study duration of 8 weeks. Results Of the 70 patients enrolled in this study, 59 (33 patients in the CITZ group and 26 patients in the SBITZ group) were included in the final analysis. In both groups, most patients were diagnosed with tinea cruris et corporis, with five or more lesions. At week 4, 11 patients (33.33%) and 17 patients (65.38%) had achieved complete cure (p<0.05), whereas 22 patients (66.67%) and 22 patients (84.61%) had achieved mycological cure (p=0.14), in the CITZ and SBITZ groups, respectively. During the observation period, recurrence was seen in 1/11 and 4/17 completely cured patients in the CITZ and SBITZ groups, respectively (p=0.15). A significant difference was noted in resolution of symptoms as well as lesions of dermatophytosis in the SBITZ group (p<0.05). Both treatments were found to be safe and well tolerated. Conclusion In the light of real-world evidence on effectiveness and safety, SBITZ should be considered as a potent therapeutic choice to effectively control the current menace of dermatophytosis in India.

[1]  G. Jain,et al.  Serum and sebum pharmacokinetics evaluation of a novel formulation of itraconazole in healthy volunteers , 2022, Indian Journal of Drugs in Dermatology.

[2]  Harshal M. Mahajan,et al.  Clinical assessment of Super bioavailable Itraconazole 50 mg in dermatophytosis (Clear 50) , 2021, IP Indian Journal of Clinical and Experimental Dermatology.

[3]  Harshal M. Mahajan,et al.  Comparative clinical effectiveness and safety of super bioavailable itraconazole and conventional itraconazole in management of dermatophytosis: a retrospective data analysis , 2021 .

[4]  S. Dogra,et al.  Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT) , 2020, Indian dermatology online journal.

[5]  Sonal Singh,et al.  The Current Indian Epidemic of Dermatophytosis: A Study on Causative Agents and Sensitivity Patterns , 2020, Indian journal of dermatology.

[6]  G. Thompson,et al.  Aspiring Antifungals: Review of Current Antifungal Pipeline Developments , 2020, Journal of fungi.

[7]  S. V. van Hal,et al.  Clinical experience with new formulation SUBA®-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies. , 2019, The Journal of antimicrobial chemotherapy.

[8]  G. Thompson,et al.  Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects , 2018, Antimicrobial Agents and Chemotherapy.

[9]  S. Dogra,et al.  Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India) , 2018, BMC Dermatology.

[10]  I. Kerridge,et al.  Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation , 2017, The Journal of antimicrobial chemotherapy.

[11]  J. Tack,et al.  Gastrointestinal behavior of itraconazole in humans - Part 1: Supersaturation from a solid dispersion and a cyclodextrin-based solution. , 2017, International journal of pharmaceutics.

[12]  S. Verma,et al.  The Great Indian Epidemic of Superficial Dermatophytosis: An Appraisal , 2017, Indian journal of dermatology.

[13]  R. Upton,et al.  Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug , 2016, Pharmaceutical Research.

[14]  S. Dogra,et al.  The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive? , 2016, Indian dermatology online journal.

[15]  R. Upton,et al.  Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States , 2015, Antimicrobial Agents and Chemotherapy.

[16]  B. Vaughn,et al.  Circadian rhythm and sleep influences on digestive physiology and disorders , 2014 .

[17]  A. Glasmacher,et al.  Making sense of itraconazole pharmacokinetics. , 2005, The Journal of antimicrobial chemotherapy.

[18]  W. Boonk,et al.  Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules: Itraconazol bei der Behandlung der Tinea corporis und Tinea cruris: Vergleich zweier Behandlungsschemata , 1998, Mycoses.

[19]  D. Rigopoulos,et al.  Itraconazole in the treatment of tinea corporis and tinea cruris , 1993, Clinical and experimental dermatology.

[20]  H. Degreef,et al.  Pharmacokinetic profile of orally administered itraconazole in human skin. , 1988, Journal of the American Academy of Dermatology.